We propose that the net effect of these changes may be to increase oxLDL uptake, to stimulate RCT, and thus to promote clearance of proatherogenic lipids from the vasculature, ultimately contributing to the cardiovascular benefits of low-intensity aerobic exercise.

No abstract

Purpose:The purpose of the study was to determine the reliability of yo-yo intermittent recovery test (yo-yo) scores and their degree of association with a 20-m shuttle run (20MSR) and VO2max values.Methods:Subjects were elite (Australian Football League [AFL], n = 23), state-level (hockey, n = 15, and cricket, n = 27), and recreational team-sport players (n = 33). All performed a 20MSR and the yo-yo at either level 1 (recreational and state level) or level 2 (AFL). A recreational subgroup (n = 19) also performed a treadmill VO2max test.Results:Test–retest results found the yo-yo (levels 1 and 2) to be reliable (ICC = .86 to .95). The 20MSR and yo-yo level 1 scores correlated (P < .01) in the recreational (r = .81 to .83) and state-level groups (r = .84 to .86), and 20MSR and yo-yo level 2 scores, in the elite (r = .86) and recreational groups (r = .55 to .57). The VO2max and yo-yo level 1 scores in the recreational group correlated (P < .01, r = .87), but no association was found with yo-yo level 2 (r = .40 to .43, non significant).Conclusions:We conclude that level 1 (recreational and state level) and level 2 (elite) yo-yo scores were both strongly associated with 20MSR scores and VO2max (level 1: recreational subjects only). The yo-yo appears to measure aerobic fitness similarly to the 20MSR but may also be used as a field test of the ability to repeat high-intensity efforts.

26

The aim of the present study was to test the hypotheses that exercise is associated with generation of peroxisome proliferator-activated receptor-γ (PPARγ) ligands in the plasma and that this may activate PPARγ signaling within circulating monocytes, thus providing a mechanism to underpin the exercise-induced antiatherogenic benefits observed in previous studies. A cohort of healthy individuals undertook an 8-wk exercise-training program; samples were obtained before (Pre) and after (Post) standardized submaximal exercise bouts (45 min of cycling at 70% of maximal O(2) uptake, determined at baseline) at weeks 0, 4, and 8. Addition of plasma samples to PPARγ response element (PPRE)-luciferase reporter gene assays showed increased PPARγ activity following standardized exercise bouts (Post/Pre = 1.23 ± 0.10 at week 0, P < 0.05), suggesting that PPARγ ligands were generated during exercise. However, increases in PPARγ/PPRE-luciferase activity in response to the same standardized exercise bout were blunted during the training program (Post/Pre = 1.18 ± 0.14 and 1.10 ± 0.10 at weeks 4 and 8, respectively, P > 0.05 for both), suggesting that the relative intensity of the exercise may affect PPARγ ligand generation. In untrained individuals, specific transient increases in monocyte expression of PPARγ-regulated genes were observed within 1.5-3 h of exercise (1.7 ± 0.4, 2.6 ± 0.4, and 1.4 ± 0.1 fold for CD36, liver X receptor-α, and ATP-binding cassette subfamily A member 1, respectively, P < 0.05), with expression returning to basal levels within 24 h. In contrast, by the end of the exercise program, expression at the protein level of PPARγ target genes had undergone sustained increases that were not associated with an individual exercise bout (e.g., week 8 Pre/week 0 Pre = 2.79 ± 0.61 for CD36, P < 0.05). Exercise is known to upregulate PPARγ-controlled genes to induce beneficial effects in skeletal muscle (e.g., mitochondrial biogenesis and aerobic respiration). We suggest that parallel exercise-induced benefits may occur in monocytes, as monocyte PPARγ activation has been linked to beneficial antidiabetic effects (e.g., exercise-induced upregulation of monocytic PPARγ-controlled genes is associated with reverse cholesterol transport and anti-inflammatory effects). Thus, exercise-triggered monocyte PPARγ activation may constitute an additional rationale for prescribing exercise to type 2 diabetes patients.